TWD 17.1
(-0.87%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 5.38 Million TWD | -45.39% |
2022 | 9.86 Million TWD | 814.09% |
2021 | 1.07 Million TWD | -80.33% |
2020 | 5.48 Million TWD | -41.61% |
2019 | 9.39 Million TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 3.11 Million TWD | 0.0% |
2024 Q2 | 3.11 Million TWD | 0.0% |
2023 FY | 5.38 Million TWD | -45.39% |
2023 Q2 | 7.63 Million TWD | 0.0% |
2023 Q1 | 7.63 Million TWD | -22.58% |
2023 Q3 | 5.38 Million TWD | -29.47% |
2023 Q4 | 5.38 Million TWD | 0.0% |
2022 Q3 | 9.86 Million TWD | 0.0% |
2022 Q4 | 9.86 Million TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Allied Biotech Corporation | 72.02 Million TWD | 92.522% |
GeneFerm Biotechnology Co., Ltd. | 76.14 Million TWD | 92.927% |
Easywell Biomedicals, Inc. | 330.44 Million TWD | 98.37% |
TTY Biopharm Company Limited | 403.04 Million TWD | 98.664% |
Synmosa Biopharma Corporation | 1.45 Billion TWD | 99.631% |
Orient EuroPharma Co., Ltd. | 2.2 Billion TWD | 99.756% |
Center Laboratories, Inc. | 4.42 Billion TWD | 99.878% |
Tien Liang BioTech Co., Ltd. | 377 Thousand TWD | -1328.647% |
Orient Pharma Co., Ltd. | 323.73 Million TWD | 98.336% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 100.83 Million TWD | 94.658% |
Excelsior Biopharma Inc. | 300.25 Million TWD | 98.206% |
DV Biomed Co., Ltd. | 315.74 Million TWD | 98.294% |
Foresee Pharmaceuticals Co., Ltd. | 13.11 Million TWD | 58.933% |
Handa Pharmaceuticals, Inc. | 7.67 Million TWD | 29.788% |
UniPharma Co., Ltd. | - TWD | -Infinity% |
Anxo Pharmaceutical Co., Ltd. | 499.69 Million TWD | 98.922% |
Alar Pharmaceuticals Inc. | 138 Thousand TWD | -3802.899% |
Winston Medical Supply Co., Ltd. | 56.05 Million TWD | 90.392% |
Mercury Biopharmaceutical Corporation | 41.66 Million TWD | 87.074% |
Bioray Biotech Co., Ltd | 65.65 Million TWD | 91.797% |
TSH Biopharm Corporation Limited | - TWD | -Infinity% |